Virtual Library

Start Your Search

Shahrokh Taghavi



Author of

  • +

    EP1.12 - Small Cell Lung Cancer/NET (ID 202)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.12-23 - Surgery Is Associated with Favorable Outcome in Patients with Early Stage SCLC – Retrospective Institutional Experience (ID 1949)

      08:00 - 18:00  |  Author(s): Shahrokh Taghavi

      • Abstract
      • Slides

      Background

      Small-cell lung cancer (SCLC) is characterized by rapid growth, early metastases and dismal outcome. Only few patients are diagnosed in early stages and thus might be candidates for potentially curative treatment. However, the value of surgery within multimodal treatment of early stage SCLC remains under debate. The aim of this study was to evaluate long-term outcome in patients with early stage SCLC undergoing curative intent surgery.

      Method

      Eligible patients with SCLC who underwent curative intent surgery at the Medical University of Vienna between 2006 and 2016 were retrospectively analyzed focusing on treatment modalities and long-term outcome.

      Result

      A total of 31 patients were included (male, n=20 (65%); median age 63.9 years). Clinical TNM-8 staging at diagnosis was stage I in 20 (65%), stage II in 5 (16%) and stage IIIA in 6 (19%) patients. 4 patients (13%) received induction chemotherapy. Sublobar resection was performed in 14 (45%) patients whereas 9 (29%) underwent lobectomy, 4 (13%) bilobectomy and 4 (13%) pneumonectomy. 24 (77%) patients received adjuvant treatment (chemotherapy, n=17 (55%); radiotherapy, n=1 (3%), chemoradiotherapy, n=5 (16%); PCI: n=8 (26%)). Median overall survival (OS) of all patients was 43.5 months, 3-years OS 58% and 5-years OS 42%, retrospectively. Patients undergoing sublobar resection had decreased median OS compared to patients undergoing lobectomy/bilobectomy/pneumonectomy (25.5 vs. 89 months, p=ns). Importantly, patients with TNM-8 stage I undergoing adjuvant chemotherapy had significantly improved OS compared to patients without adjuvant treatment (median OS 44 vs. 12 months, p=0.01).

      Conclusion

      This institutional experience shows good long-term outcome after adequate surgical resection followed by adjuvant treatment in selected patients with early stage SCLC. Our data indicate that sublobar resection should be avoided, however, well designed prospective trials are required to define the optimal treatment modalities in these patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    EP1.17 - Treatment of Early Stage/Localized Disease (ID 207)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment of Early Stage/Localized Disease
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.17-15 - Comparison of Long-Term Outcome of Wedge Resection, Anatomical Segmentectomy and Lobectomy in Stage I-II Non-Small Cell Lung Cancer (Now Available) (ID 2423)

      08:00 - 18:00  |  Author(s): Shahrokh Taghavi

      • Abstract
      • Slides

      Background

      In patients with early stage non-small cell lung cancer (NSCLC) lobectomy is still considered the treatment of choice, whereas sublobar resection is more frequently performed in patients with reduced lung function and high perioperative risk. We investigated long term outcome of patients undergoing either lobectomy or anatomical segmentectomy or wedge resection for early stage NSCLC.

      Method

      In this retrospective cohort study patients with early stage NSCLC who underwent either lobectomy or anatomical segmentectomy or wedge resection at our center between 2006 and 2018 were analyzed. Primary endpoint was overall survival (OS) and disease-free survival (DFS).

      Result

      383 patients with peripherally located stage I or II NSCLC (TNM 8) who underwent curative intent surgery were identified. Patients undergoing neoadjuvant or adjuvant treatment or with centrally located tumors were excluded. 325 patients (84.8%) received lobectomy, 26 patients (6.8%) anatomical segmentectomy and 32 patients (8.4%) wedge resection. Pathological stage was IA 221 (57.7%), IB 93 (24.3%), IIA 48 (12.5%), IIB (3.9%). Histology revealed adenocarcinoma in 285 (74.4%), squamous cell lung cancer 98 (25.6%). There was no significant difference regarding OS and DFS between all three groups. Interestingly, in patients with tumors larger than 2cm there was also no significant difference in OS and DFS between all groups.

      Conclusion

      The relevance of sublobar resection in early stage NSCLC patients is still controversial. In our cohort study the long-term outcome of anatomical segmentectomy and wedge resection was comparable to outcome after lobectomy. However, well-designed prospective randomized studies are necessary to confirm the value of sublobar resections for stage I and II NSCLC.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.15 - Thymoma/Other Thoracic Malignancies (ID 185)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Thymoma/Other Thoracic Malignancies
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.15-11 - Favorable Long Term Survival After Initially Palliative Resection for a Giant Primary Rib Osteosarcoma with Severe Mediastinal Shifting  (Now Available) (ID 2440)

      10:15 - 18:15  |  Author(s): Shahrokh Taghavi

      • Abstract
      • Slides

      Background

      Osteosarcoma is the most common malignancy of the bone with high morbidity and mortality. Treatment of choice is chemotherapy (CHT) followed by surgery and adjuvant CHT. Primary rib osteosarcoma is a rare disease. We present a case of a young patient with a giant primary rib osteosarcoma undergoing palliative resection.

      Method

      A 29-year-old woman presented with dyspnea and pain in the left chest wall in August 2012. Computed tomography (CT) showed a large lesion destructing the 3rdleft rib with extension to the left upper lobe. Biopsy revealed an osteoplastic osteosarcoma and staging examinations showed no distant metastases (DM).

      Result

      CHT by the EURAMOS-1-protocol was started but was discontinued by the patient after 1 cycle due to side effects. 1.5 years later without any treatment or follow up, the patient was re-admitted with massive thoracic pain, severity of dyspnea and in a very limited general condition. CT showed a major tumor progression with severe mediastinal shift and total atelectasis of the left lung. Due to extreme large tumor size and lack of treatment alternatives, surgery in palliative intent was performed: clamshell incision, complete resection of the tumor including chest wall reconstruction. The postoperative course was challenging but she recovered well and was discharged after several months with no evidence of disease in combined positron-emission-tomography/CT. Thereafter, the patient again refused any further treatment and checkups. 4.5 years later she presented again with local recurrence in the left chest wall and in excellent overall condition without evidence for DM. Accordingly, a re-thoracotomy, partial resection of ribs 6-9, left diaphragm and pericardium and reconstruction was performed. The postoperative course was without complications and the surgery was well-tolerated.

      Conclusion

      This case report shows an unexpected favorable outcome after resection in palliative intent for a giant primary rib osteosarcoma with severe mediastinal shifting. Currently, 7 years after diagnosis, the patient is free from disease.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.